News headlines about Petmed Express (NASDAQ:PETS) have been trending positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Petmed Express earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.4638214687092 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
Shares of Petmed Express (NASDAQ:PETS) traded down $0.21 during mid-day trading on Wednesday, hitting $45.52. The stock had a trading volume of 12,639 shares, compared to its average volume of 716,882. The firm has a market capitalization of $924.37, a price-to-earnings ratio of 26.93, a PEG ratio of 2.55 and a beta of 0.93. Petmed Express has a fifty-two week low of $19.21 and a fifty-two week high of $57.80.
Petmed Express (NASDAQ:PETS) last posted its earnings results on Monday, January 22nd. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.33 by $0.11. The firm had revenue of $60.10 million for the quarter, compared to analyst estimates of $56.76 million. Petmed Express had a return on equity of 34.04% and a net margin of 12.84%. Petmed Express’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the company earned $0.24 earnings per share. research analysts predict that Petmed Express will post 1.76 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, February 16th. Investors of record on Monday, February 5th were issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 2.20%. This is a positive change from Petmed Express’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Friday, February 2nd. Petmed Express’s dividend payout ratio (DPR) is 59.17%.
A number of equities analysts have commented on the stock. ValuEngine upgraded shares of Petmed Express from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. BidaskClub downgraded shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 19th. Finally, Northcoast Research set a $58.00 price target on shares of Petmed Express and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. Petmed Express presently has a consensus rating of “Hold” and a consensus price target of $42.80.
In related news, Director Gian Fulgoni sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $44.38, for a total transaction of $887,600.00. Following the sale, the director now directly owns 55,900 shares of the company’s stock, valued at $2,480,842. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronald J. Korn sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $48.38, for a total value of $241,900.00. Following the sale, the director now directly owns 68,833 shares in the company, valued at $3,330,140.54. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 65,000 shares of company stock worth $3,229,500. 4.00% of the stock is owned by corporate insiders.
Petmed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.